Evidence map›Paper›PMID 22415006›Full record

ArticlemBio2012

Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosis.

Matthew C Mulvey, Katherine A Sacksteder, Leo Einck, Carol A Nacy

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in mBio, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. The Spermidine Synthase Gene as a Reporter of Transcription Inhibition inInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. True facets of TB diagnosis in 2012: Hypes and realities.European journal of microbiology & immunology · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Matthew C MulveySequella, Inc., Rockville, Maryland, USA.
Katherine A Sacksteder
Leo Einck
Carol A Nacy
Sequella (United States) · US

Funding

Development of a phage-based nucleic acid amplification diagnostic for the rapid R43AI077167 · NIAID · SEQUELLA, INC. · PI MULVEY, MATTHEW CHARLES · 2008 to 2008
$244k
NIAID NIH HHS 1R43AI077167-01NIAID NIH HHS R43 AI077167
6 · The paper itself

Abstract

unlabelledWe designed, constructed, and evaluated a prototype novel reporter system comprised of two functional cassettes: (i) the SP6 RNA polymerase gene under transcriptional control of a promoter active in mycobacteria and (ii) the consensus SP6 polymerase promoter that directs expression of an otherwise unexpressed sequence. We incorporated the reporter system into a mycobacteriophage for delivery into viable Mycobacterium tuberculosis, and introduction led to synthesis of an SP6 polymerase-dependent surrogate marker RNA that we detected by reverse transcriptase PCR (RT-PCR). The reporter confirmed the susceptibility profile of both drug-susceptible and drug-resistant M. tuberculosis strains exposed to first-line antitubercular drugs and required as little as 16 h of exposure to antibacterial agents targeting bacterial metabolic processes to accurately read the reaction. The reporter system translated the bacterial phenotype into a language interpretable by rapid and sensitive nucleic acid detection. As a phenotypic assay that works only on viable M. tuberculosis, it could be used to rapidly assess resistance to any drug, including drugs for which the mechanism of resistance is unknown or which result from many potential known (and unknown) genetic alterations. IMPORTANCE: The ability to detect antibiotic resistance of slow-growing bacteria (i.e., Mycobacterium tuberculosis) is hampered by two factors, the time to detection (weeks to months) and the resistance mechanism (unknown for many drugs), delaying the appropriate treatment of patients with drug-resistant or multidrug-resistant tuberculosis (TB). The novel technique described in this article uses a unique surrogate nucleic acid marker produced by phage that infects M. tuberculosis to record phenotypic antibiotic susceptibility in less than a day.

Indexed as

Genes, ReporterAntitubercular AgentsDNA-Directed RNA PolymerasesHumansMicrobial Sensitivity TestsMycobacteriophagesMycobacterium tuberculosisPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTime FactorsTransduction, GeneticAntitubercular AgentsDNA-Directed RNA PolymerasesRNA, MessengerRNA polymerase SP6

Identifiers

PMID22415006
PMCPMC3312217
OpenAlexW2072678363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.